Table 1.

Overall demographics and baseline characteristics (safety population)

	Placebo (n = 6)	CBD (n = 28)	Total (N = 34)
Age (years)	26.9 ± 7.0	30.1 ± 11.1	29.5 ± 10.5
Sex
Male	5 (83)	17 (61)	22 (65)
Female	1 (17)	11 (39)	12 (35)
Race, white	6 (100)	28 (100)	34 (100)
Height (cm)	178.3 ± 6.9	174.3 ± 13.5	175.0 ± 12.6
Weight (kg)	86.0 ± 18.3	81.9 ± 22.2	82.7 ± 21.4
Body mass index (kg/m2)	27.0 ± 5.3	26.8 ± 5.4	26.8 ± 5.3

STP arm	Placebo (n = 2)	CBD (n = 12)	Total (n = 14)
Daily STP dose (mg/day)	1250 (500–2000)	625 (500–2000)	625 (500–2000)
No. receiving any AEDa	2 (100)	11 (92)	13 (93)
Most common AEDs (≥ 10%) in any treatment group
Lacosamide	2 (100)	3 (25)	5 (36)
Clobazam	0 (0)	4 (33)	4 (29)
VPA	0 (0)	3 (25)	3 (21)
Ethosuximide	0 (0)	2 (17)	2 (14)
Lamotrigine	0 (0)	2 (17)	2 (14)
Topiramate	0 (0)	2 (17)	2 (14)
VPA sodium	0 (0)	2 (17)	2 (14)
Levetiracetam	1 (50)	0 (0)	1 (7)
Rufinamide	1 (50)	0 (0)	1 (7)

VPA arm	Placebo (n = 4)	CBD (n = 16)	Total (n = 20)
Daily VPA dose (mg/day)	1450 (900–2500)	1015 (200–1950)	1115 (200–2500)
No. receiving any AEDa	4 (100)	16 (100)	20 (100)
Most common AEDs (≥ 10%) in any treatment group
Lacosamide	0 (0)	3 (19)	3 (15)
Clobazam	0 (0)	6 (38)	6 (30)
Lamotrigine	2 (50)	4 (25)	6 (30)
Carbamazepine	1 (25)	1 (6)	2 (10)
Levetiracetam	0 (0)	2 (13)	2 (10)
Lorazepam	1 (25)	1 (6)	2 (10)
Oxcarbazepine	1 (25)	1 (6)	2 (10)
Rufinamide	1 (25)	2 (13)	3 (15)
Clonazepam	1 (25)	2 (13)	3 (15)
Zonisamide	0 (0)	2 (13)	2 (10)

Data are presented as mean ± standard deviation, n (%), or median (range) unless otherwise indicated

AED antiepileptic drug, CBD cannabidiol, STP stiripentol, VPA valproate

^aOther than VPA or STP as required for each arm